Sustainability Investment Suanfarma is actively expanding environmental infrastructure including a wastewater treatment plant, PV solar installations, and utility upgrades, signaling strong sustainability commitments that can be leveraged to position the company as a partner for green chemistry and compliant, eco-friendly manufacturing.

Acquisition Momentum Post-acquisition by ArchiMed in 2021, Suanfarma has scaled into a globally recognized nutraceutical ingredients leader, suggesting a growth trajectory and expanded capability set that can be aligned with customers seeking integrated CDMO services across fermentation and chemical synthesis.

Global Reach With 12 local offices and a customer base spanning 70+ countries and over 400 clients, Suanfarma offers a broad geographic footprint suitable for multinational partnerships, regional supply continuity, and rapid onboarding for global API projects.

One Stop Shop Capabilities cover development, scaling, manufacturing, and commercialization of APIs (innovative or generic) in both fermentation and chemical synthesis, enabling upsell opportunities for full lifecycle support and complex project management.

Strategic Partnerships Ongoing collaborations in anti-infective API development and precision fermentation, plus recent senior leadership changes, indicate openness to co-development, strategic alliances, and expanded portfolio opportunities in high-demand therapeutic areas.